Introduction: We present a case of simultaneous robot-assisted radical nephroureterectomy (RANU) and robot-assisted radical cystectomy (RARC) for muscle-invasive bladder cancer with concomitant upper urinary tract urothelial carcinoma.
Case Presentation: A 59-year-old Japanese man was diagnosed with right ureteral cancer and muscle-invasive bladder cancer. We performed RANU and RARC simultaneously; three of the ports used for RANU were diverted to RARC. Console times for RANU and RARC were 66 and 207 minutes, respectively. Total operative time was 386 minutes. The intraoperative blood loss was estimated 255 ml. The patient was discharged on postoperative day 18 without complications.
Conclusion: We reported our experience with simultaneous RANU and RARC for muscle-invasive bladder cancer with concomitant right ureteral cancer. To the best of our knowledge, this is the first report of its kind in Japan.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807340 | PMC |
| http://dx.doi.org/10.1002/iju5.12534 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis.
BMC Urol
January 2025
Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
Background: Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes.
View Article and Find Full Text PDFDoes Bladder Outlet Obstruction Releated to Recurrence In Low Risk Ta Low Grade Non Muscle Invasive Bladder Cancer?
Clin Genitourin Cancer
December 2024
Esenler Maternity and Child Diseases Hospital, Department of Urology, Istanbul, Turkey.
Introduction: Bladder cancer is common in men. The number of recurrences is one of the risk factors for progression and poor prognosis in nonmuscle invasive bladder cancer (NMIBC). We aimed to investigate whether bladder outlet obstruction (BOO) has an effect on bladder cancer recurrence in patients with nonmuscle invasive bladder cancer.
View Article and Find Full Text PDFIdentification of multicohort-based predictive signature for NMIBC recurrence reveals SDCBP as a novel oncogene in bladder cancer.
Ann Med
December 2025
Central Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Despite surgical and intravesical chemotherapy interventions, non-muscle invasive bladder cancer (NMIBC) poses a high risk of recurrence, which significantly impacts patient survival. Traditional clinical characteristics alone are inadequate for accurately assessing the risk of NMIBC recurrence, necessitating the development of novel predictive tools.
Methods: We analyzed microarray data of NMIBC samples obtained from the ArrayExpress and GEO databases.
Impact of HER2 Expression on the Prognosis of Muscle-Invasive Bladder Cancer Patients Treated with Bladder-Preservation Comprehensive Therapy.
Biol Proced Online
January 2025
Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China.
Background: HER2 expression has been confirmed to be associated with bladder cancer aggressiveness. Anti-HER2 RC48-ADC is approved in China for the treatment of patients with advanced urothelial carcinoma with failed chemotherapy who are HER2 positive (IHC 2 + or 3 +). The discovery of HER2 positivity in urothelial carcinoma and the development of anti-HER2 drugs have brought new hope for bladder preservation treatment in MIBC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!